Anti-Human VIPR1 Recombinant Antibody (hu23A11) (CAT#: TAB-359CQ)

Recombinant monoclonal antibody to VIPR1. The antibody is capable of neutralizing the PACAP-induced cAMP increase.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
FuncS

Figure 1 Effect of anti-VPAC1 monoclonal antibody 23A11 on the in vitro megakaryopoiesis.

Figure 1 Effect of anti-VPAC1 monoclonal antibody 23A11 on the in vitro megakaryopoiesis.

Sca1+ murine bone marrow cells incubated with 23A11 resulted in increased numbers of CFU-MKs after 12 days. Bars represent the mean±SD (P<0.01).

FC

Figure 2 Effect of anti-VPAC1 monoclonal antibody 23A11 on the in vitro megakaryopoiesis.

Figure 2 Effect of anti-VPAC1 monoclonal antibody 23A11 on the in vitro megakaryopoiesis.

FACS analysis showing the percentage of CD41+ megakaryocytes derived from human CD34+ cord blood cells in the absence (left two panels) or presence (right two panels) of anti-VPAC1 monoclonal antibody 23A11, on day 5 (upper two panels) or day 14 (lower two panels).

FuncS

Figure 3 Effect of anti-VPAC1 monoclonal antibody on busulfan-induced thrombocytopenia.

Figure 3 Effect of anti-VPAC1 monoclonal antibody on busulfan-induced thrombocytopenia.

Platelet count in mice following administration of anti-VPAC1 monoclonal antibody 23A11 (filled squares) or PBS (filled circles) on days 0, 3 and 7 and busulfan treatment on days 7 and 10. Each point represents the mean platelet count from 5 (filled squares) or 3 (filled circles) mice ±SD. **P<0.01 by ANOVA.

FuncS

Figure 4 Effect of anti-PACAP and anti-VPAC1 monoclonal antibody on busulfan-induced thrombocytopenia.

Figure 4 Effect of anti-PACAP and anti-VPAC1 monoclonal antibody on busulfan-induced thrombocytopenia.

Platelet count in mice following administration of anti-PACAP monoclonal antibody (circles) and anti-VPAC1 monoclonal antibody 23A11 (squares) or PBS (diamonds) on days 0, 3 and 7 and busulfan treatment on days 7 and 10. Each point represents the mean platelet count from 6 mice.


Specifications

  • Host Species
  • Human
  • Type
  • Humanized antibody
  • Specificity
  • Human
  • Species Reactivity
  • Human
  • Clone
  • hu23A11
  • Applications
  • FC, FuncS
  • Related Disease
  • Thrombocytopenia

Applications

  • Application Notes
  • This antibody has been reported for use in Flow Cytometry, Functional Assay.

Target

  • Alternative Names
  • VIPR1; vasoactive intestinal peptide receptor 1; II; HVR1; RDC1; V1RG; VIPR; VIRG; VAPC1; VPAC1; VPAC1R; VIP-R-1; VPCAP1R; PACAP-R2; PACAP-R-2

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone hu23A11"

See other products for "VIPR1"

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-359CQ. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare